A group of six leading Alzheimer’s experts have convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease.

Just a month after it gave the new Alzheimer's drug aducanumab (Aduhelm) the green light, the FDA decided to change the label.

In a watershed moment for the field, the U.S. Food and Drug Administration yesterday approved the first Alzheimer’s treatment that tackles the underlying disease pathology.

Aducanumab is the first disease-modifying treatment to be approved for Alzheimer's Disease (AD) and the first to target amyloid ß (Aß), which is one of the earliest causative steps in the pathophysiology of AD.